undamentalytics Newsletter
Sign in

Dolby Laboratories, Inc. (DLB) stock

Add to watchlist

Add holding +

NYSE: DLB NYSE Application Software Next results ~November 17, 2026

C+ Fundamentals grade

Dolby Laboratories, Inc. is a US-listed company in the application software industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$52

Cash-flow model

Base case. Range ~$41–$67 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 21% above our base value.

Price used: $63.28, November 2, 2026

Dolby Laboratories, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 9 selling0 purchases and 38 sales by directors and officers, last 12 monthsInsider trades
  • Funds187 adding, 221 cuttingOf 60 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Dolby Laboratories files

Where Dolby Laboratories stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.35bn, up 0.6% on a year earlier, slower than 3.4% a quarter earlier. That puts it 811 of 931 for growth among all the companies we cover. Free-cash-flow margin fell to 29.0% from 32.5% a year earlier. Operating margin narrowed to 17.7% from 20.9%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $50.35 a share, against a share price of $62.05. At that price, our model says the market is pricing in about 6.3% a year of cash-flow growth for five years, faster than the 1.1% a year revenue growth it has delivered.

Source: 10-Q filed July 30, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 17, 2026 (estimated)

Dolby Laboratories, Inc.'s trailing-twelve-month revenue grew 0.6% year on year, with a free-cash-flow margin of 29.0%. Where it stands out: gross margin of 87.6% ranks 9 of 160 application software companies we cover. Where it lags: revenue growth of 0.6% ranks 152 of 184 application software companies we cover.

Our discounted-cash-flow model values the business at ~$52 per share in the base case (~$41–$67 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Net margin compressing: TTM net margin fell to 16.7%, down 2.9pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Strong cash generation. 29.0% of revenue turned into free cash flow, against a median of 15.2% for application software companies we cover.
  • Shrinking share count. Diluted shares fell 1.2% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.7bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 17 November; the share price can move sharply on the day.
  • Margins narrowing. Operating margin is down 3.3 points on a year ago.
  • Insiders selling. 9 insiders sold $15M of stock over the past 365 days and none bought (87% under pre-set trading plans).
  • Growth easing. The growth rate is 2.8 points lower than a quarter earlier.
  • Below peers: revenue growth. Revenue growth of 0.6% ranks 152 of 184 application software companies we cover (median 12.0%).
  • Below peers: change in growth rate. Change in growth rate of -2.8pp ranks 143 of 184 application software companies we cover (median +0.2pp).

Latest results: FY2026 Q3

Filed July 30, 2026
Earnings per share
$0.69 against an average estimate of $0.67: beat by 3.0%
Revenue
$305m, down 3.3% on a year earlier
Share reaction
+11.9% in the first session after the results on July 30, 2026, against +2.4% for the S&P 500
Guidance given
total revenue $362m to $392m (fourth quarter of fiscal 2026); licensing revenue $335m to $365m (fourth quarter of fiscal 2026)
Next report
November 17, 2026; average EPS estimate $1.20

Dolby Laboratories' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.1%
  • 1 week+0.3%
  • 1 month+7.5%
  • This year+0.3%
  • 1 year-2.4%
  • 5 years-23.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.4B
Operating margin
17.7%
Net margin
16.7%
EPS (TTM, diluted)
$2.35

Growth

Revenue growth
+0.6%
Change in growth rate
−2.8 pts
Share count change
−1.2%

Cash

Free cash flow (TTM)
$393M
FCF margin
29.0%
Stock pay % of revenue
9.6%

Earnings

Last results
July 30, 2026
Next results (est.)
November 17, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Product
  3. Announcement
  4. Product
  5. Announcement
  6. Leadership
  7. Announcement
  8. Announcement
  9. Results
  10. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Dolby Laboratories, Inc. valuation models and calculator

What the price is pricing in

The share price implies about 6.7% a year of cash-flow growth for five years.That is faster than the 1.1% a year revenue growth Dolby Laboratories has delivered.

  • Priced in6.7%
  • Last 12 months0.6%
  • 3 years a year1.7%
  • 5 years a year1.1%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($63.58, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$52
Price used
$63.58close November 3, 2026
Implied change
▼ 18%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Dolby Laboratories, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($246M, FY2026 Q3 TTM), growing 5.9% and 2.2% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$41–~$67 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Dolby Laboratories, Inc.'s free cash flow after stock-based pay ( $246M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Dolby Laboratories, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$52 ~$41–$67 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$63 ~$52–$110 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$26 ~$19–$36 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$26 ~$22–$31 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$44 ~$26–$63 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Dolby Laboratories, Inc. with Application Software in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −23%
  • Revenue growth 5 points higher ▲ +30%
  • Free-cash-flow margin 1 point lower ▼ −3%
  • Last year's free-cash-flow margin change, if it persists ▼ −10%
  • Discount rate 1 point higher ▼ −13%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $45$58$76$99$130$170
8.5% $36$46$58$75$97$125
10% $30$38$48$61$77$99

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$47.30$50.69$62.30$57.48$59.35$85.25$60.83$75.03$72.66$70.75$63.28
Market value$4.8bn$5.2bn$6.7bn$6.0bn$6.1bn$8.9bn$6.2bn$7.3bn$7.1bn$6.9bn$6.1bn
+ Net debt (− = net cash)−$520m−$634m−$918m−$797m−$1.1bn−$1.2bn−$620m−$745m−$482m−$702m−$669m
Enterprise value$4.3bn$4.6bn$5.7bn$5.2bn$5.0bn$7.7bn$5.6bn$6.6bn$6.6bn$6.2bn$5.4bn
Multiples
Price / sales 4.7x4.8x6.3x4.8x5.3x7.0x4.9x5.6x5.6x5.1x4.5x
Price / earnings 26.1x25.4x159.7x23.6x26.4x28.8x33.7x36.5x27.0x27.0x26.9x
Price / free cash flow 18.7x18.8x23.9x26.0x22.0x22.7x22.9x21.8x23.8x15.8x15.5x
EV / EBITDA 13.6x13.9x21.7x15.2x16.3x17.5x18.9x22.1x19.7x17.6x16.3x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

72 /100

Strong moat

How hard Dolby Laboratories's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 17.4% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 88.3%, moving by 0.9 percentage points (standard deviation) across 10 years.

  • Durability 16 / 20

    Operating margin has been a median 18.7%; its worst year was 16.6%.

  • Cash conversion 20 / 20

    Free cash flow was positive in 10 of 10 years, at a median 24.7% of revenue.

  • Discipline 11 / 20

    The diluted share count fell 7.4% over five years; stock-based pay has been a median 8.3% of revenue.

AI disruption exposure: High. In this industry, the core product is information work that AI systems increasingly perform. The score above includes a 15-point deduction for that exposure (87 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 17, 2026, after the close. Analysts expect revenue of $373m and EPS of $1.20 (range $1.15 to $1.22) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $4.32 +2% $1.4bn +6%
Next $4.58 +6% $1.5bn +3%

Next year's EPS estimate has moved −0.1% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.1% on 90 days ago. In the last 30 days, 2 analysts raised Dolby Laboratories, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Dolby Laboratories, Inc., last 90 days
$4.30 $4.40 $4.50 $4.60 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $4.32 Current fiscal year, 60 days ago: $4.33 Current fiscal year, 30 days ago: $4.32 Current fiscal year, 7 days ago: $4.32 Current fiscal year, Now: $4.32 $4.32 Next fiscal year, 90 days ago: $4.59 Next fiscal year, 60 days ago: $4.60 Next fiscal year, 30 days ago: $4.58 Next fiscal year, 7 days ago: $4.58 Next fiscal year, Now: $4.58 $4.58

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $4.32$4.59
60 days ago $4.33$4.60
30 days ago $4.32$4.58
7 days ago $4.32$4.58
Now $4.32$4.58

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.67 $0.69 +3.0%
Mar 2026 $1.34 $1.37 +2.5%
Dec 2025 $0.99 $1.06 +6.7%
Sept 2025 $0.70 $0.99 +40.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, July 30, 2026
  • Total revenue full year of fiscal 2026 $1.41bn to $1.44bn
    “Total revenue is expected to range from $1.41 billion to $1.44 billion.” source
  • Total revenue fourth quarter of fiscal 2026 $362m to $392m
    “Total revenue is expected to range from $362 million to $392 million.” source
  • Diluted earnings per share full year of fiscal 2026 $2.62 to $2.77 GAAP
    “Diluted earnings per share is anticipated to range from $2.62 to $2.77 on a GAAP basis and from $4.25 to $4.40 on a non-GAAP basis.” source
  • Diluted earnings per share full year of fiscal 2026 $4.25 to $4.40 Non-GAAP
    “Diluted earnings per share is anticipated to range from $2.62 to $2.77 on a GAAP basis and from $4.25 to $4.40 on a non-GAAP basis.” source
  • Diluted earnings per share fourth quarter of fiscal 2026 $0.78 to $0.93 GAAP
    “Diluted earnings per share is anticipated to range from $0.78 to $0.93 on a GAAP basis and from $1.13 to $1.28 on a non-GAAP basis.” source
  • Diluted earnings per share fourth quarter of fiscal 2026 $1.13 to $1.28 Non-GAAP
    “Diluted earnings per share is anticipated to range from $0.78 to $0.93 on a GAAP basis and from $1.13 to $1.28 on a non-GAAP basis.” source
Show 16 more items
  • Gross margins full year of fiscal 2026 about 88% GAAP
    “Gross margins are anticipated to be approximately 88% on a GAAP basis and approximately 90% on a non-GAAP basis.” source
  • Gross margins full year of fiscal 2026 about 90% Non-GAAP
    “Gross margins are anticipated to be approximately 88% on a GAAP basis and approximately 90% on a non-GAAP basis.” source
  • Operating margins full year of fiscal 2026 about 21% GAAP
    “Dolby expects operating margins to be approximately 21% on a GAAP basis and to be approximately 34% on a non-GAAP basis.” source
  • Operating margins full year of fiscal 2026 about 34% Non-GAAP
    “Dolby expects operating margins to be approximately 21% on a GAAP basis and to be approximately 34% on a non-GAAP basis.” source
  • Gross margins fourth quarter of fiscal 2026 about 88% GAAP
    “Gross margins are anticipated to be approximately 88% on a GAAP basis and approximately 90% on a non-GAAP basis.” source
  • Gross margins fourth quarter of fiscal 2026 about 90% Non-GAAP
    “Gross margins are anticipated to be approximately 88% on a GAAP basis and approximately 90% on a non-GAAP basis.” source
  • Licensing revenue full year of fiscal 2026 $1.31bn to $1.34bn
    “Licensing revenue is expected to range from $1.31 billion to $1.34 billion.” source
  • Operating expenses full year of fiscal 2026 $937m to $947m GAAP
    “Operating expenses are anticipated to range from $937 million to $947 million on a GAAP basis and from $785 million to $795 million on a non-GAAP basis.” source
  • Operating expenses full year of fiscal 2026 $785m to $795m Non-GAAP
    “Operating expenses are anticipated to range from $937 million to $947 million on a GAAP basis and from $785 million to $795 million on a non-GAAP basis.” source
  • Effective tax rate full year of fiscal 2026 about 24% GAAP
    “Effective tax rate is anticipated to be around 24% on a GAAP basis and around 21% on a non-GAAP basis.” source
  • Effective tax rate full year of fiscal 2026 about 21% Non-GAAP
    “Effective tax rate is anticipated to be around 24% on a GAAP basis and around 21% on a non-GAAP basis.” source
  • Licensing revenue fourth quarter of fiscal 2026 $335m to $365m
    “Licensing revenue is expected to range from $335 million to $365 million.” source
  • Operating expenses fourth quarter of fiscal 2026 $227m to $237m GAAP
    “Operating expenses are anticipated to range from $227 million to $237 million on a GAAP basis and from $195 million to $205 million on a non-GAAP basis.” source
  • Operating expenses fourth quarter of fiscal 2026 $195m to $205m Non-GAAP
    “Operating expenses are anticipated to range from $227 million to $237 million on a GAAP basis and from $195 million to $205 million on a non-GAAP basis.” source
  • Effective tax rate fourth quarter of fiscal 2026 about 23% GAAP
    “Effective tax rate is anticipated to be around 23% on a GAAP basis and around 21% on a non-GAAP basis.” source
  • Effective tax rate fourth quarter of fiscal 2026 about 21% Non-GAAP
    “Effective tax rate is anticipated to be around 23% on a GAAP basis and around 21% on a non-GAAP basis.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Dolby Laboratories, Inc.'s revenue by +5.9% next year and +2.2% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+7.6%, weight 49%) , management guidance (+7.5%, weight 22%) and the company's own record (+2.0%, weight 29%) . How the weights are set.

Analyst recommendations

4 analysts, Oct 2026
Buy375%
Hold125%
Sell00%

Monthly trend

  1. Oct 20261214
  2. Sep 20261214
  3. Aug 20261214
  4. Jul 20261214

Counts of recommendations published by analysts covering Dolby Laboratories, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.5%
of tradable shares
Days to cover
7.01
at average volume
Short interest, 1 month
+8%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.9%
of shares
Employees
2,051
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −2.4%

$64.82 on October 31, 2025 to $63.28

ThenNowEffect
Revenue (last 12 months) $1.3bn $1.4bn +0.6%
Net margin 19.6% 16.7% −14.9%
P/E multiple 23.9x 26.9x +12.7%
Share count 97m 96m +1.2%

Biggest factor: net margin.

Last 3 years −21.1%

$80.21 on November 3, 2023 to $63.28

ThenNowEffect
Revenue (last 12 months) $1.3bn $1.4bn +5.2%
Net margin 17.0% 16.7% −1.9%
P/E multiple 35.8x 26.9x −24.9%
Share count 98m 96m +1.8%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
DLB−1%−25%+24%−8%−16%+0%
Industry peers (median)−8%−50%+19%+2%−21%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
DLB58%42%67%42%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
DLB−19%−34%−16%−22%−25%−29%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 49% from May 4, 2021 to July 14, 2026. Getting back needed a 97% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$48.23 – $68.26
From 52-week high
−7.3%
vs 50-day average
+4.2%
vs 200-day average
+7.5%
Volatility (1 year)
30%
Beta vs S&P 500
0.55

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±7.1%
After a week
6 up, 6 down
typical move ±6.3%
After a month
6 up, 6 down
typical move ±6.0%
Results releasedNext dayS&P 500 next day5 days21 days
July 30, 2026 +11.9% +2.4% +15.9% +17.7%
April 30, 2026 −9.2% +1.3% −9.2% −10.8%
January 29, 2026 +4.9% −0.5% +4.5% +7.0%
November 18, 2025 +0.7% −0.5% +4.4% +4.0%
July 31, 2025 −7.4% −2.0% −5.0% −4.9%
May 1, 2025 −2.5% +2.2% −2.4% −3.2%
January 29, 2025 +8.3% +0.1% +4.8% +1.6%
November 19, 2024 +14.9% +0.4% +12.6% +9.0%
August 7, 2024 −7.6% +1.6% −4.7% −6.5%
May 2, 2024 +5.8% +2.2% +6.7% +4.5%
February 1, 2024 −3.5% +2.4% −3.0% −0.3%
November 16, 2023 −8.0% +0.2% −2.5% −2.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Dolby Laboratories, Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade C+ (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

DLB Dolby Laboratories, Inc. Grade C+ $63.25

Own 100 shares, sell the $65.00 call expiring December 18, 2026 (46 days) for $2.25 a share — $225 per contract.

Previous session · Bid $2.25, ask $2.70, quoted Mon 2 Nov, 17:21 New York time with DLB at $63.25. Option prices move with the shares: check the live chain at your broker before trading.

  • If DLB ends below $65.00: you keep your shares and the $225 — 3.6% extra on the position, 28.2% a year at that pace.
  • If it ends above $65.00: your shares are sold at $65.00, a total return of 6.3% including the premium — at or above our value of ~$52.
$400 $0 −$1.2k Our value $52.00 Break-even $61.00 Price $63.25
Profit or loss per contract at expiry, by share price (including the shares bought at today's price).
Premium
$225
Annualised
28.2%
Break-even
$61.00
Max gain
$400
Chance of selling
~46%

Results are expected around November 17, 2026, before this option expires: the share price can jump on results, and the premium partly reflects that.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Dolby Laboratories, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Dolby Laboratories, Inc.
$1.3B $1.3B $1.4B $1.4B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $1.3B Revenue (TTM), FY24 Q1: $1.3B Revenue (TTM), FY24 Q2: $1.3B Revenue (TTM), FY24 Q3: $1.3B Revenue (TTM), FY24 Q4: $1.3B Revenue (TTM), FY25 Q1: $1.3B Revenue (TTM), FY25 Q2: $1.3B Revenue (TTM), FY25 Q3: $1.3B Revenue (TTM), FY25 Q4: $1.3B Revenue (TTM), FY26 Q1: $1.3B Revenue (TTM), FY26 Q2: $1.4B Revenue (TTM), FY26 Q3: $1.4B $1.4B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $1.3B
FY24 Q1 $1.3B
FY24 Q2 $1.3B
FY24 Q3 $1.3B
FY24 Q4 $1.3B
FY25 Q1 $1.3B
FY25 Q2 $1.3B
FY25 Q3 $1.3B
FY25 Q4 $1.3B
FY26 Q1 $1.3B
FY26 Q2 $1.4B
FY26 Q3 $1.4B
Revenue growth, TTM YoY Dolby Laboratories, Inc.
-5% 0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 3.7% Revenue growth, TTM YoY, FY24 Q1: 3.5% Revenue growth, TTM YoY, FY24 Q2: -0.7% Revenue growth, TTM YoY, FY24 Q3: -2.2% Revenue growth, TTM YoY, FY24 Q4: -2.0% Revenue growth, TTM YoY, FY25 Q1: 2.7% Revenue growth, TTM YoY, FY25 Q2: 4.0% Revenue growth, TTM YoY, FY25 Q3: 6.9% Revenue growth, TTM YoY, FY25 Q4: 5.9% Revenue growth, TTM YoY, FY26 Q1: 1.8% Revenue growth, TTM YoY, FY26 Q2: 3.4% Revenue growth, TTM YoY, FY26 Q3: 0.6% 0.6%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 3.7%
FY24 Q1 3.5%
FY24 Q2 -0.7%
FY24 Q3 -2.2%
FY24 Q4 -2.0%
FY25 Q1 2.7%
FY25 Q2 4.0%
FY25 Q3 6.9%
FY25 Q4 5.9%
FY26 Q1 1.8%
FY26 Q2 3.4%
FY26 Q3 0.6%
Operating margin (TTM) Dolby Laboratories, Inc.
14% 16% 18% 20% 22% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 16.6% Operating margin (TTM), FY24 Q1: 14.7% Operating margin (TTM), FY24 Q2: 14.8% Operating margin (TTM), FY24 Q3: 16.6% Operating margin (TTM), FY24 Q4: 20.3% Operating margin (TTM), FY25 Q1: 20.7% Operating margin (TTM), FY25 Q2: 20.5% Operating margin (TTM), FY25 Q3: 20.9% Operating margin (TTM), FY25 Q4: 19.6% Operating margin (TTM), FY26 Q1: 18.5% Operating margin (TTM), FY26 Q2: 18.5% Operating margin (TTM), FY26 Q3: 17.7% 17.7%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 16.6%
FY24 Q1 14.7%
FY24 Q2 14.8%
FY24 Q3 16.6%
FY24 Q4 20.3%
FY25 Q1 20.7%
FY25 Q2 20.5%
FY25 Q3 20.9%
FY25 Q4 19.6%
FY26 Q1 18.5%
FY26 Q2 18.5%
FY26 Q3 17.7%
FCF margin (TTM) Dolby Laboratories, Inc.
20% 25% 30% 35% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 25.9% FCF margin (TTM), FY24 Q1: 22.6% FCF margin (TTM), FY24 Q2: 28.8% FCF margin (TTM), FY24 Q3: 21.1% FCF margin (TTM), FY24 Q4: 23.3% FCF margin (TTM), FY25 Q1: 30.0% FCF margin (TTM), FY25 Q2: 29.6% FCF margin (TTM), FY25 Q3: 32.5% FCF margin (TTM), FY25 Q4: 32.3% FCF margin (TTM), FY26 Q1: 28.8% FCF margin (TTM), FY26 Q2: 22.1% FCF margin (TTM), FY26 Q3: 29.0% 29.0%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 25.9%
FY24 Q1 22.6%
FY24 Q2 28.8%
FY24 Q3 21.1%
FY24 Q4 23.3%
FY25 Q1 30.0%
FY25 Q2 29.6%
FY25 Q3 32.5%
FY25 Q4 32.3%
FY26 Q1 28.8%
FY26 Q2 22.1%
FY26 Q3 29.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Dolby Laboratories took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $1.3B
  2. Other income $37.1M · 2.7%
  3. Cost of revenue $160M · 11.9%
  4. Gross profit $1.2B · 88.1%
  5. Research and development $262M · 19.4%
  6. Selling, general and admin $647M · 48.0%
  7. Other operating costs $15M · 1.1%
  8. Operating income $265M · 19.6%
  9. Income tax $47M · 3.5%
  10. Net income $255M · 18.9%

Shares of revenue. Source: Dolby Laboratories's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Sept 2009 2010 Sept 2010 2011 Sept 2011 2012 Sept 2012 2013 Sept 2013 2014 Sept 2014 2015 Sept 2015 2016 Sept 2016 2017 Sept 2017 2018 Sept 2018 2019 Sept 2019 2020 Sept 2020 2021 Sept 2021 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025 LTM Jun 2026
Income
Revenue 720 923 961 933 910 960 971 1,026 1,080 1,055 1,242 1,162 1,281 1,254 1,300 1,274 1,349 1,354
Gross profit 655 791 850 841 813 890 876 917 962 927 1,081 1,015 1,151 1,112 1,147 1,133 1,189 1,187
EBITDA 392 464 474 406 299 327 282 317 331 265 342 310 440 295 298 334 353 332
Operating income 364 429 430 362 245 274 213 232 247 184 257 219 344 207 216 258 265 239
Net income 243 283 309 264 189 206 181 186 206 42 255 231 310 184 201 262 255 226
Diluted EPS $2.11 $2.46 $2.75 $2.46 $1.84 $1.99 $1.75 $1.81 $2.00 $0.39 $2.44 $2.25 $2.97 $1.81 $2.05 $2.69 $2.62 $2.35
Growth (year on year)
Revenue +12.4% +28.2% +4.2% −2.9% −2.5% +5.6% +1.1% +5.7% +5.3% −2.4% +17.7% −6.4% +10.3% −2.1% +3.7% −2.0% +5.9% +0.6%
EBITDA +25.9% +18.3% +2.0% −14.3% −26.5% +9.5% −13.7% +12.2% +4.6% −20.1% +29.2% −9.5% +42.2% −33.0% +1.1% +11.9% +5.7% −10.0%
Operating income +26.8% +18.1% +0.1% −15.8% −32.2% +11.6% −22.1% +8.7% +6.6% −25.7% +40.1% −14.9% +57.4% −40.0% +4.4% +19.7% +2.6% −15.1%
Net income +21.8% +16.6% +9.1% −14.5% −28.4% +8.9% −12.0% +2.5% +11.1% −79.8% +511.2% −9.3% +34.1% −40.7% +9.0% +30.5% −2.6% −14.4%
Diluted EPS +21.3% +16.6% +11.8% −10.5% −25.2% +8.2% −12.1% +3.4% +10.5% −80.5% +525.6% −7.8% +32.0% −39.1% +13.3% +31.2% −2.6% −13.4%
Margins
Gross margin 91.0% 85.7% 88.4% 90.1% 89.4% 92.7% 90.2% 89.4% 89.0% 87.9% 87.0% 87.4% 89.9% 88.7% 88.3% 89.0% 88.1% 87.6%
EBITDA margin 54.5% 50.3% 49.3% 43.5% 32.8% 34.1% 29.1% 30.9% 30.7% 25.1% 27.6% 26.7% 34.4% 23.5% 23.0% 26.2% 26.1% 24.5%
Operating margin 50.5% 46.5% 44.7% 38.8% 27.0% 28.5% 22.0% 22.6% 22.9% 17.4% 20.7% 18.8% 26.9% 16.5% 16.6% 20.3% 19.6% 17.7%
Net margin 33.8% 30.7% 32.2% 28.3% 20.8% 21.5% 18.7% 18.1% 19.1% 4.0% 20.5% 19.9% 24.2% 14.7% 15.4% 20.6% 18.9% 16.7%
Free-cash-flow margin 36.0% 31.4% 37.1% 23.9% 27.5% 29.8% 15.6% 25.3% 25.8% 26.5% 18.6% 23.9% 30.7% 21.6% 25.9% 23.3% 32.3% 29.0%
Cash flow
Cash from operations 273 327 404 390 277 362 309 360 378 352 328 344 448 319 367 327 472 438
Capital spending 14 37 47 167 27 75 158 101 100 73 96 66 54 48 30 30 36 45
Free cash flow 259 290 356 223 250 286 152 259 278 279 231 278 393 271 337 297 436 393
Stock-based pay 22 29 44 48 64 66 67 67 65 71 77 87 100 115 118 120 129 130
Free cash flow after stock pay 237 261 313 175 185 221 85 192 213 208 155 191 294 156 218 177 307 263
Balance sheet
Cash 452 546 552 493 454 568 532 520 634 918 797 1,072 1,225 620 745 482 702 669
Total debt 6 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −446 −541 −552 −493 −454 −568 −532 −520 −634 −918 −797 −1,072 −1,225 −620 −745 −482 −702 −669
Diluted shares 115m 115m 113m 108m 103m 104m 104m 102m 103m 107m 105m 103m 105m 102m 98m 97m 97m 96m
Returned to shareholders
Dividends — — 0 0 408 0 41 48 57 66 77 89 89 100 103 115 127 134
Buybacks — 241 192 268 82 56 107 101 100 150 341 174 246 530 149 160 125 235
Total returned — 241 192 268 490 56 148 149 157 217 418 262 335 631 253 275 252 369

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 26, 2026
What it owns · $3.2bn
Short-term assets $1.3bnLonger-term assets $1.8bn
What it owes, and who funded it · $3.1bn
Short-term liabilities $416mLonger-term liabilities $148mShareholders' equity $2.6bn
  • Short-term assets cover short-term liabilities $1.3bn of assets due within a year against $416m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.3bn short-term assets against $148m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Dolby Laboratories, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$235M
Dividends (TTM)
$134M
Returned to shareholders
94%
of free cash flow
Buybacks, last 3 fiscal years
$434M
Diluted share count
−1.2%
year over year
Total shareholder yield
6.2%
dividends 2.2% + buybacks 3.9% of market value
Dividend payout ratio
59%
of net income paid out
R&D spending
19.6%
of revenue
Days sales outstanding
77 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in application software
Last 12 months unless stated DLB KC KVYO PCOR GTM SRAD Median
Revenue, last 12 months $1.4bn $1.3bn $1.4bn $1.4bn $1.3bn $1.5bn $482m
Revenue growth, last 12 months 0.6% 22.9% 28.9% 15.4% 2.7% 21.8% 12.0%
Revenue growth, 3-year average 1.7% — 33.4% 19.6% 1.6% — 11.1%
Revenue growth, latest quarter −3.3% — 26.4% 15.8% 1.2% — 11.9%
Gross margin 87.6% 15.7% 73.8% 80.0% 83.5% 85.2% 69.2%
Operating margin 17.7% −8.1% −1.9% −4.9% −35.2% — 1.1%
Operating margin, 3-year average 18.4% — −19.2% −10.0% −2.6% — −0.8%
Net margin 16.7% −9.8% 0.5% −2.7% −43.0% 7.8% 2.1%
Cash from operations / revenue 32.3% 39.8% 19.9% 25.9% 34.9% 31.2% 18.2%
Free-cash-flow margin 29.0% 13.8% 18.2% 24.4% 28.5% 30.9% 15.0%
Free-cash-flow margin, 3-year average 27.5% — 16.2% 18.0% 28.3% — 16.2%
Stock pay / revenue 9.6% 4.7% 12.3% 17.5% 8.6% 4.3% 9.3%
Change in share count −1.2% 12.3% 10.0% 1.3% — — 2.2%

Median of all 185 companies we cover in application software. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

185 application software companies
Measure Company Peer median Rank
Revenue growth Growth 0.6% 12.0% 152 of 184
Change in growth rate Growth -2.8pp +0.2pp 143 of 184
Gross margin Profitability 87.6% 69.8% 9 of 160
Operating margin Profitability 17.7% 1.1% 38 of 181
Net margin Profitability 16.7% 2.1% 38 of 185
Free-cash-flow margin Cash generation 29.0% 15.2% 31 of 180
Stock pay as % of revenue Cash generation 9.6% 9.3% 95 of 177
Change in share count Balance sheet -1.2% 1.7% 52 of 163
Days sales outstanding Balance sheet 77 days 57 days 115 of 162

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to September 26, 2025
Products and services
Line of business Revenue Share YoY
Total Licensing Revenue $1.2B 92.5% ▲ 5.6%
Licensing Brodcast Revenue $428M 34.3% ▲ 4.7%
Licensing Mobile Revenue $269M 21.5% ▲ 13.9%
Licensing Other Revenue $248M 19.9% ▲ 8.1%
Licensing PC Revenue $152M 12.2% ▲ 7.5%
Licensing CE Revenue $151M 12.1% ▼ 9.1%
Products and Services $101M 7.5% ▲ 10.0%
Geography
Region Revenue Share YoY
Outside the US $852M 63.2% ▲ 3.5%
United States $497M 36.8% ▲ 10.4%

From Dolby Laboratories, Inc.'s 10-K filed November 18, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$3.3B
Institutions reporting
387
Shares held vs prior quarter
▲ 5.2%
Positions opened / closed
45 / 72

Top buyers and sellers, Q2 2026: 187 institutions bought and 221 sold ; the biggest buyer was Bank Of Montreal (+1.4M shares) and the biggest seller AQR Capital Management LLC (−790K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $351M 6.7M 10.8% ▲ 2.1%
Vanguard Portfolio Management LLC $260M 5.0M 8.0% ▼ 0.4%
Bank Of New York Mellon Corp $253M 4.8M 7.8% ▲ 7.1%
Morgan Stanley $242M 4.6M 7.4% ▼ 10.5%
Vanguard Capital Management LLC $143M 2.7M 4.4% ▼ 0.2%
First Trust Advisors LP $142M 2.7M 4.4% ▲ 20.0%
State Street Corp $122M 2.3M 3.7% ▲ 1.2%
Acadian Asset Management LLC $99.7M 1.9M 3.1% ▲ 20.8%
Geode Capital Management, LLC $96.9M 1.8M 3.0% ▲ 4.4%
FMR LLC $83.4M 1.6M 2.6% ▲ 56.6%
Dimensional Fund Advisors LP $81.9M 1.6M 2.5% ▲ 17.9%
Bank Of Montreal $76.6M 1.5M 2.4% ▲ 11641.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Dolby Laboratories, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $14.7M 38 trades by 9 insiders · 87% under pre-set plans
Net ▼ $14.7M net selling
Insider Date Trade Shares Price Value
Couling John D SVP, Entertainment October 1, 2026 Sell pre-set plan 836 $59.33 $49,598
Couling John D SVP, Entertainment October 1, 2026 Sell pre-set plan 6,831 $58.72 $401,092
Couling John D SVP, Entertainment September 1, 2026 Sell pre-set plan 7,667 $61.05 $468,070
Nicholson Ryan VP, CAO and Corp. Controller August 25, 2026 Sell 1,183 $65.28 $77,226
Revankar Shriram SVP, Advanced Technology Group August 14, 2026 Sell pre-set plan 3,000 $62.71 $188,130
Nicholson Ryan VP, CAO and Corp. Controller August 10, 2026 Sell 1,348 $62.04 $83,630
Nicholson Ryan VP, CAO and Corp. Controller August 4, 2026 Sell 357 $60.63 $21,645
Couling John D SVP, Entertainment August 3, 2026 Sell pre-set plan 6,884 $60.11 $413,797
Couling John D SVP, Entertainment August 3, 2026 Sell pre-set plan 783 $59.03 $46,220
Couling John D SVP, Entertainment July 1, 2026 Sell pre-set plan 7,667 $53.20 $407,884
Couling John D SVP, Entertainment June 1, 2026 Sell pre-set plan 508 $56.16 $28,529
Couling John D SVP, Entertainment June 1, 2026 Sell pre-set plan 7,158 $55.59 $397,913

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 10 trades and filings

No trades in Dolby Laboratories, Inc. disclosed in the last 12 months; 10 earlier trades on record.

  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded September 25, 2025, filed October 22, 2025
  • Lisa C. McClain(R-MI 9):Purchase, $1,001 - $15,000, traded September 11, 2025, filed October 22, 2025
  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded August 4, 2025, filed September 12, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 17, 2026 estimated from the company's past filing pattern, not announced

  • July 30, 2026
  • April 30, 2026
  • January 29, 2026
  • November 18, 2025
  • July 31, 2025
  • May 1, 2025

Recent SEC filings

Data status

When each part of this page on Dolby Laboratories, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Dolby Laboratories, Inc. in brief

What does Dolby Laboratories, Inc. do?
Dolby Laboratories, Inc. is a US-listed company in the application software industry. Its financial year ends in September.
What is Dolby Laboratories, Inc.'s stock ticker?
Dolby Laboratories, Inc. trades under the ticker DLB on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Dolby Laboratories, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Dolby Laboratories, Inc. reported revenue of $1.4B, 0.6% higher than a year earlier, according to its SEC filings.
What is Dolby Laboratories, Inc.'s free cash flow?
Dolby Laboratories, Inc.'s free-cash-flow margin is 29.0% of revenue over the trailing twelve months, ranking 31 of the 180 application software companies we cover.
What is Dolby Laboratories, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Dolby Laboratories, Inc.'s free cash flow after stock-based pay gives ~$52 per share in the base case, and ~$41–$67 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Dolby Laboratories, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Portfolio Management LLC and Bank Of New York Mellon Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Dolby Laboratories, Inc. buying back stock, and does it pay a dividend?
Dolby Laboratories, Inc. spent $235M on share repurchases over the trailing twelve months, and its diluted share count fell 1.2% over the year.
What is Dolby Laboratories, Inc.'s market cap?
On November 2, 2026, Dolby Laboratories, Inc.'s market capitalisation was about $6.1B, with a price-to-earnings ratio of 26.9 and net debt of -$669M. Market figures come from third-party market data and may be delayed.
Does Dolby Laboratories, Inc. pay a dividend?
Yes: Dolby Laboratories, Inc. paid $134M in dividends over the trailing twelve months, a dividend yield of 2.24% and a payout ratio of 59.4%.
Who are Dolby Laboratories, Inc.'s competitors?
In our Application Software peer group, the companies closest to Dolby Laboratories, Inc. are Kingsoft Cloud Holdings Ltd, Klaviyo, Inc., Procore Technologies, Inc., Zoominfo Technologies Inc. and Sportradar Group AG. The side-by-side comparison below sets their revenue, margins and growth against Dolby Laboratories, Inc.'s.
Are insiders buying or selling Dolby Laboratories, Inc. stock?
Over the last 12 months, Dolby Laboratories, Inc.'s directors and officers reported 0 open-market purchases and 38 sales on Form 4. The insider trading page charts every trade.
When is Dolby Laboratories, Inc.'s next earnings date?
Around November 17, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Dolby Laboratories, Inc. announces its own schedule.